Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2004, Vol. 2 ›› Issue (6): 421-425.doi: 10.3736/jcim20040605

• Original Clinical Research • Previous Articles     Next Articles

Clinical study on idiopathic thrombocytopenic purpura treated with Shengxueling Granule

Yong-ming Zhou1, Ming-hui Hu1, Jing-ming Yang2, Wen-wei Zhu1, Zhen-qiao Huang1, Shao-hong Zhou1, Yi Xu1, Jia-hui Lu1#br#   

  1. 1. Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
    2. Department of Hematology, Xinhua Hospital, Shanghai Second Medical University, Shanghai 200092, China
  • Received:2004-07-01 Online:2004-11-20 Published:2018-10-20

Objective: To observe the clinical effect of Shengxueling Granule (SXLG) in treating idiopathic thrombocytopenic purpura (ITP), and to study its possible mechanism.Methods: Eighty-six cases of ITP were divided into two groups randomly. Fifty-six cases in the treatment group were treated with SXLG, a traditional Chinese medicine, and 30 cases administered with Western medicine (prednisone) were taken as control. Patients in each group took drugs for three months and were under follow-up observation.Results: In SXLG-treated group, the total effective rate in 3 months was 85.71%, similar to 83.33% in prednisone-treated group (P>0.05), while the total effective rate in 6 months in the SXLG-treated group was 91.07%, higher than 53.33% of the prednisone-treated group (P<0.01), and no obvious side-effects were observed. The patients’ bleeding was alleviated or stopped, and their general condition was improved. And the blood platelet count (BPC) was increased, the platelet associated immunoglobulin (PAIg) and interleukin-4 (IL-4) were markedly dropped, the level of natural killer cells activity (NKCA) increased, and the rate of T lymphocyte subsets gradually returned to normal level. Megakaryocytes tended toward maturation on bone marrow smear after SXLG treatment. All differences above were statistically significant.Conclusion: SXLG is an effective and safe medicine for ITP. It can regulate the cellular immunity, inhibit the platelet antibody to reduce the destruction of the platelet and to increase the number of platelet, promote the differentiation and maturation of megakaryocyte, facilitate the production and release of platelet, lower the fragility of capillary, and prevent the hemorrhagic tendency.

Key words: Shengxueling Granule, purpura, thrombocytopenic, idiopathic, traditional Chinese medical therapy

CLC Number: 

  • R289.5

"

Group n Grading of hemorrhage
SXLG-treated group
Before treatment 56 6 14 34 2
After treatment 30 19 6 5 0
Pednisone-treated group
Before treatment 30 3 8 18 1
After treatment 13 8 3 2 0

Tab 2

Comparison of therapeutic effects between SXLG- and pednisone-treated groupsCases (%)"

Group n Significantly
effective
Moderately
effective
Improved Ineffective Total effective rate
SXLG-treated group
After 3 months treatment 56 9(16.07) 17(30.36) 22(39.29) 8(14.28) 48(85.71)
After 6 months treatment 56 17(30.36) 25(44.64) 9(16.07) 5(8.93) 51(91.07)**
Pednisone-treated group
After 3 months treatment 30 3(10.00) 12(40.00) 10(33.33) 5(16.67) 25(83.33)
After 6 months treatment 30 1(3.33) 6(20.00) 9(30.00) 14(46.67) 16(53.33)

"

Group n PAIgG PAIgA PAIgM
SXLG-treated group
Before treatment 56 73.67±45.50 12.74±10.26 11.16±7.48
After treatment 56 33.20±24.68△△ 7.08±5.92△△ 7.68±5.86△△
Pednisone-treated group
Before treatment 30 71.63±43.73 11.96±9.78 10.90±6.65
After treatment 30 29.14±23.65△△ 6.02±3.69△△ 6.32±3.75△△

Tab 4

Changes of NKCA and IL-4 before and after SXLG treatment ($\bar{x}$±s )"

Group n NKCA (%) IL-4 (kU/L)
SXLG-treated group
Before treatment 36 13.26±6.28 74.16±15.48
After treatment 36 17.49±5.96△△ 63.22±12.36△△
Normal control group 20 20.30±6.50 58.65±6.68

Tab 5

Changes of T lymphocyte subsets before and after SXLG treatment ($\bar{x}$±s )"

Group n CD+3(%) CD+4(%) CD+8(%) CD+4/CD+8
SXLG-treated group
Before treatment 30 52.63±8.66▲▲ 36.64±5.06▲▲ 27.84±5.20 1.32±0.26▲▲
After treatment 30 62.14±9.10△△▲ 41.26±6.82△△ 22.98±4.82△△ 1.79±0.32△△
Normal control group 20 68.20±10.07 43.72±6.12 24.65±5.32 1.81±0.25

Tab 6

Changes of bone marrow megakaryocytes before and after SXLG treatment ($\bar{x}$±s, %)"

Time n Megakaryoblast and
promegakaryocyte
Granular
megakaryocyte
Platelet-producing
Megakaryocyte
Naked-nuclear
megakaryocyte
Before treatment 36 14.66±9.82 69.68±12.18 4.26±3.04 11.40±8.06
After treatment 36 20.02±10.08 59.79±13.36△△ 10.94±8.76△△ 9.25±6.69
[1] 张之南, 沈悌 . 血液病诊断及疗效标准(第2版)[M]. 北京: 科学出版社, 1999,( 第2版):279-282
[2] 陈丙莺, 马建吟, 黄钦田 , 等. 简易自然杀伤试验—LDH释放改良法[J]. 上海免疫学杂志, 1989,9(4):218-219
[3] 全国中医学会内科学会. 特发性血小板减少性紫癜出血程度分级标准[S]. 北京中医学院学报, 1984,7(4):25-27.
[4] Viganaux F, Golstein P . Fas-based lymphocyte-mediated cytotoxicity against syngeneic activated lymphocytes: a regulatory pathway[J]. Eur J Immunol, 1994,24(4):923-927
doi: 10.1002/(ISSN)1521-4141
[5] McFarland J . Pathophysiologyof platelet destruction in immune(idiopathic) thrombocytopenic purpura[J]. Blood Rev, 2002,16(1):1-2
doi: 10.1054/blre.2001.0169
[1] Xue-qing Yu, Shu-guang Yang, Yang Xie, Jian-sheng Li. Traditional Chinese medicine in the treatment of idiopathic pulmonary fibrosis based on syndrome differentiation: Study protocol of exploratory trial. Journal of Integrative Medicine, 2020, 18(2): 163-168.
[2] Hui-hua Zhu, Yan-ping Chen, Jian-er Yu, Min Wu, Zhan Li. Therapeutic effect of Xincang Decoction on chronic airway inflammation in children with bronchial asthma in remission stage. Journal of Chinese Integrative Medicine, 2005, 3(1): 23-27.
[3] Xiao-yi Zhang, Cheng-bao Kuang. Clinical observation on treatment of nonalcoholic fatty liver disease complicating hyperuricemia by Zhifang Ⅰ Decoction. Journal of Chinese Integrative Medicine, 2004, 2(4): 265-267.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Chan Chen, Yong-mei Meng , Peng Zhang, Juan Wang, Hui-hui Zhao, Shu-zhen Guo , Wei Wang. Diagnosis and treatment rule of traditional Chinese medicine for syndrome factors of chronic congestive heart failure: a study based on Shannon entropy method. Journal of Chinese Integrative Medicine, 2010, 8(11): 1080-1084
[2] Xiang-ying Mao , Qin Bian , Zi-yin Shen. Analysis of the osteogenetic effects exerted on mesenchymal stem cell strain C3H10T1/2 by icariin via MAPK signaling pathway in vitro. Journal of Chinese Integrative Medicine, 2012, 10(11): 1272-1278
[3] Zhi-rong Zhu, Chang-chun Zeng, Li Yang, Han-ping Liu, Song-hao Liu. Influence of brightness value of supranasal point and apex nasi on dominant wavelength and excitation purity in complexion inspection of healthy adults. Journal of Chinese Integrative Medicine, 2011, 9(12): 1333-1338
[4] Yong-hong Li, Zong-wen Huang, Ping Xue, Jia Guo, Fu-qian He, Zheng You, Zheng-rong Wang. Effects of Chaiqin Chengqi Decoction on activation of nuclear factor-κB in pancreas of rats with acute necrotizing pancreatitis. Journal of Chinese Integrative Medicine, 2008, 6(2): 180-184
[5] Liu Yue, Xie Ming, Zhang Ye. Dynamic changes of laboratory parameters of rats with type 2 diabetes and insulin resistance: defining their role in development of traditional Chinese medicine syndrome. Journal of Chinese Integrative Medicine, 2012, 10(1): 100-108
[6] Zhao-guo Li . Comparative study on WHO Western Pacific Region and World Federation of Chinese Medicine Societies international standard terminologies on traditional medicine: Diseases of Paediatrics (Part 1). Journal of Integrative Medicine, 2015, 13(1): 61-64
[7] Chuan-yue Niu. Methods of English translation for Huangdi Neijing. Journal of Chinese Integrative Medicine, 2005, 3(2): 160-163
[8] Yan-hao Xiong, Ning Du, Wei-zhen Chen, Tao Liu, Xu-sheng Tang. Retrospective study of the relationship of height difference and bone density of postmenopausal women. Journal of Chinese Integrative Medicine, 2003, 1(4): 265-267
[9] Zhen-ye Xu, Jian-wen Liu, Mei-yun Zhou. Effects of Xuanyinning Recipe on invasion of SPC-A-1 cells and pathomorphological changes of peritoneum in mice inoculated with sarcoma 180. Journal of Chinese Integrative Medicine, 2005, 3(4): 282-285
[10] Jia-xu Chen, Fei-fei Xue. Origin and development of microcosmic syndrome differentiation. Journal of Chinese Integrative Medicine, 2005, 3(5): 342-346